6998 — Genor Biopharma Holdings Balance Sheet
0.000.00%
- HK$1.98bn
- HK$870.57m
- CNY206.23m
- 21
- 11
- 86
- 30
Annual balance sheet for Genor Biopharma Holdings, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 2,930 | 2,201 | 1,589 | 1,165 | 1,059 |
| Net Total Receivables | 136 | 133 | 82.7 | 68.6 | 8.5 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 3,101 | 2,387 | 1,720 | 1,241 | 1,067 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 229 | 223 | 205 | 60.1 | 5.82 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 3,573 | 2,863 | 2,115 | 1,447 | 1,290 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 249 | 313 | 260 | 230 | 122 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 339 | 373 | 313 | 258 | 138 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 3,234 | 2,490 | 1,802 | 1,189 | 1,151 |
| Total Liabilities & Shareholders' Equity | 3,573 | 2,863 | 2,115 | 1,447 | 1,290 |
| Total Common Shares Outstanding |